Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for treatment of hematologic cancers

A blood and cancer technology, applied in the field of treatment of blood cancer and composition, can solve the problem that CVA21 cannot obtain cell entry and infect host cells

Active Publication Date: 2007-10-31
MERCK & CO INC
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although CVA21 can bind DAF, ICAM-1 is a key receptor for CVA21 cell infection - in the absence of ICAM-1 expression on the cell surface, CVA21 cannot gain cellular entry and infect host cells under normal conditions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treatment of hematologic cancers
  • Methods and compositions for treatment of hematologic cancers
  • Methods and compositions for treatment of hematologic cancers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0142] The present invention will now be described in detail with reference to specific examples, but the scope of the invention should not be limited thereby.

[0143] Materials and methods

[0144] cells and viruses

[0145] The prototype strain of group A Coxsackievirus CVA21 (Kuykendall strain) was obtained from Dr M. Kennett, Enterorespiratory Laboratory, Fairfield Hospital, Melbourne, Victoria, Australia. CVA21 was double plaque purified and grown in ICAM-1 expressing myeloma cells (SK-Mel-28). Viruses are laboratory-saved strains of CVA21, CVA18, CVA15, and CVA13. Prototype strains of these group A coxsackieviruses CVA13 (Flores), CVA15 (G-9), CVA18 (G-13) and CVA21 (Kuykendall) were also obtained from Dr M. Kennett. Initially, CVA13, CVA15 and CVA18 were propagated in HeLa-B cells, while CVA21 Kuykendall was propagated in RD-ICAM-1 cells. Working laboratory strains of these viruses were then prepared from these preserved strains in SK-Mel-28 cells.

[0146]SK-Mel-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to oncolytic picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed Picornavirus such as Coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation.

Description

technical field [0001] The present invention relates to oncolytic picornaviruses and methods and compositions for treating subjects with hematological cancers. Background technique [0002] Blood cancers are cancers of the "blood system". These cancers usually affect white blood cells (disease- and infection-fighting cells) rather than red blood cells (oxygen-carrying cells). Some of these cancers develop in the bone marrow, where all blood cells are made. Some occur in lymph nodes and other lymphoid tissues through which white blood cells flow. Common cancers of white blood cells are leukemia, Hodgkin lymphoma, other lymphomas, and multiple myeloma. [0003] Multiple myeloma (MM) is a B-cell malignancy that occurs in approximately 1% of all types of human cancer and is more common than myeloid leukemia or Hodgkin's disease. [0004] Multiple myeloma can cause anemia, severe bone pain, and in some cases pathological fractures, increased chances of infection, hypercalcemi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/125A61P35/00A61P35/02
CPCY02A50/30
Inventor G·G·奥D·R·雪弗伦
Owner MERCK & CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com